Motive’s Entitlement Server Acknowledged as a Pacesetter in Counterpoint Research’s 2025 Rankings
5.9.2025 15:00:00 CEST | Business Wire | Press release
Motive, a global leader in device management, today announced its recognition as a Pacesetter in Counterpoint Research’s 2025 Entitlement Server Rankings. Counterpoint placed Motive in its highest top-right Pacesetter quadrant: the most advanced recognition in the ranking.
This accolade reflects Motive’s decisive investment in entitlement orchestration at a time when operators face urgent deadlines, including Apple’s September 2025 RCS requirement. Motive has taken the lead, proving ability to deliver at scale, currently deployed in large mobile service providers across North America, Europe, Africa, the Middle East, Asia-Pacific, and Latin America.
Removing Barriers to RCS and Beyond
The industry has long wrestled with the lack of a commercial framework for Rich Business Messaging (RBM) and lack of cross platform support between Android and iOS. Motive addresses this by ensuring operators can enable RCS on both Apple and Android devices securely without delay. This approach derisks operator investment by making entitlement orchestration a multi-purpose platform for innovation, not a single-use bet.
Motive’s Entitlement Server supports a wide range of simultaneous use-cases including eSIM onboarding for primary and secondary devices, Phone Number Verification (PNV) through silent SIM-based authentication, CBRS offload, satellite enablement for D2C/D2D, automotive IoT integration, and 5G on-demand slicing.
This breadth ensures operators can respond to new device, service, and revenue models without costly customization or delays.
Setting the Pace for the Industry
“Motive’s recognition as a Pacesetter underscores what our customers already realize - we are the leading full featured supplier of entitlement orchestration deployed at global scale,” said Jeevithan Muttu, VP Product and R&D, Motive. “We invested early to make sure operators were ready for Apple’s September 2025 deadline and Motive is giving operators the flexibility to innovate, differentiate, and monetize faster than ever before.”
Accelerating Monetization of Network Investments
Operators are under mounting pressure to monetize billions already invested in 5G, slicing, and new spectrum. Motive has responded with sustained R&D across its purpose-build telecom software suite. These capabilities demonstrate Motive’s unmatched ability to help operators accelerate digital transformation and monetize connectivity across mobile, home, and IoT domains.
In addition to entitlement orchestration, Motive leads the market on multiple fronts including broadband CPE, IoT, and device & service management provisioning for carriers, having previously earned similar Pacesetter standing in other segments of the market.
About Motive
Motive empowers the world’s leading telecom operators to deliver seamless digital services through its suite of operator-first platforms. From entitlement orchestration to device and service management, Motive enables operators to accelerate digital transformation and monetize connectivity across mobile, home, and IoT networks.
For more information, visit www.motive.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250905207059/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom